CT
BMY.RT

Caldwell Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Caldwell Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,262
Closed -$23 – 733
2020
Q4 		$23 Sell
2,262
-32
-1% -$68 ﹤0.01% 715
2020
Q3 		$23 Sell
2,294
-91
-4% -$260 ﹤0.01% 721
2020
Q2 		$24 Sell
2,385
-33
-1% -$119 ﹤0.01% 758
2020
Q1 		$24 Sell
2,418
-16
-0.7% -$53 ﹤0.01% 793
2019
Q4 		$24 Buy
+2,434
New +$6.33K ﹤0.01% 801

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Caldwell Trust's BMY.RT Position: Q1 2021 in Review

Caldwell Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 2,262 shares — an estimated $23 sold.

Caldwell Trust first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $24 in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Caldwell Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Caldwell Trust sold 2,262 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $23.
  • Caldwell Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Caldwell Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $24 in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Caldwell Trust's 13F filing for Q1 2021, filed 2 Oct 2025.